Tyrosine kinase inhibition in acute myeloid leukemia

Author： Altman Jessica K. Szilard Amy K. Platanias Leonidas C.

ISSN： 1042-8194

Source： Leukemia and Lymphoma, Vol.54, Iss.7, 2013-07, pp. : 1351-1352

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Chronic Myeloid Leukemia: The Value of Tyrosine Kinase Inhibition

By Tariq I. Mughal John M. Goldman

American Journal of Cancer, Vol. 2, Iss. 5, 2003-01 ,pp. : 305-311

Adis International

Access to resources Recommend Favorite

Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia

Current Cancer Therapy Reviews, Vol. 4, Iss. 1, 2008-02 ,pp. : 31-49

Bentham Science Publishers

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 8, 2009-10 ,pp. : 853-863

Bentham Science Publishers

Access to resources Recommend Favorite

Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia

Current Cancer Therapy Reviews, Vol. 9, Iss. 3, 2013-08 ,pp. : 181-219

Bentham Science Publishers

Access to resources Recommend Favorite

Synergistic effect of alltrans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells

Molecular Medicine Reports, Vol. 11, Iss. 5, 2015-01 ,pp. : 3969-3975

Spandidos Publications

Access to resources Recommend Favorite